Improving asthma treatment using inhaler technology

ottingham University Hospitals NHS Trust0 个研究点目标入组 36 人开始时间: 2017年1月31日最近更新: 2022年4月19日

适应症

试验速览

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35257874/ (added 28/03/2022)

•1. Age 18-65 inclusive
•2. Use of systemic corticosteroids for worsening asthma (or an increase from baseline dose in patients on long-term oral corticosteroids) in the prior 12 months (i.e. at least one asthma exacerbation requiring additional systemic corticosteroid in the prior 12 months) patient reported
•3. Doctor’s diagnosis of asthma for at least 12 months
•4. On BTS step 2-5 treatment via MDI
•5. Use of own internet-enabled and compatible mobile phone
•6. Participant is willing and able to give informed consent for participation in the clinical investigation
•7. Able (in the Investigators opinion) and willing to comply with all clinical investigation requirements
•8. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the clinical investigation

•1. Diagnosis of COPD or onset of symptoms after the age of 40 in patients with =10 PYH of smoking
•2. Other clinically significant coexisting respiratory disease e.g. fibrosis, bronchiectasis
•3. No personal mobile smartphone
•4. Patients on maintenance and reliever therapy (Symbicort ‘SMART’ or Fostair 'MART’)
•5. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the clinical investigation, or may influence the result of the clinical investigation, or the participant’s ability to participate in the clinical investigation

发起方

ottingham University Hospitals NHS Trust